Research programme: Huntington's disease RNAi therapies - AmpliPhi Biosciences

Drug Profile

Research programme: Huntington's disease RNAi therapies - AmpliPhi Biosciences

Alternative Names: AAV-siRNA; AAV1.shHD2.1; shHD2.1; short hairpin RNAs for Huntington's disease

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Sirna Therapeutics; Targeted Genetics
  • Developer AmpliPhi Biosciences Corporation; University of Iowa
  • Class RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Huntington's disease

Most Recent Events

  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 09 Mar 2011 Targeted Genetics Corporation is now called AmpliPhi Biosciences
  • 24 Jan 2008 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top